Table 1. Studies of sorafenib + RFA and lenvatinib + RFA.
| Arm | BCLC stage | CP class | Age (years) | Tumor size (cm) | Tumor number | TKI periods (day) | On/Off TKI with RFA | Results of efficacy | |
|---|---|---|---|---|---|---|---|---|---|
| Sorafenib | |||||||||
| Fukuda (6) | RFA (N=30) | A | A, B | 72.8 | <3; 2.23±0.43 | Single | 7 days before RFA | No break | Ablated area (long- and short-axis dimensions); SOR + RFA is better |
| SOR + RFA (N=15) | |||||||||
| Feng (7) | RFA (N=64) | 0-B1 | A | 49.7 | ≤7; 3.09±1.97 | ≤3 | Within 60 days before or after RFA | No break | Recurrence rate OS; SOR + RFA is better |
| SOR + RFA (N=64) | |||||||||
| Kan (8) | RFA (N=32) | B, C | A, B | 53.7 | 3.1–5.0 | Single | After first RFA and continuous before or after the new RFA | No break | Recurrence rate, time to progression; SOR + RFA is better |
| SOR + RFA (N=30) | |||||||||
| Gong (9) | RFA (N=50) | A | A | 55.7 | 2.6±1.4 | 1.4 | 28 days after RFA | – | Tumor-free survival, relapse rate, survival rate; SOR + RFA is better |
| SOR + RFA (N=40) | |||||||||
| Lenvatinib | |||||||||
| Wang (10) | LEN (N=13) | B2 | A | 76.1 | 4.8±3.2 | 4 (1–12) | Additional RFA: about 3 months after start of lenvatinib | 4 days off: pre RFA; 7–10 days on: post RFA | Best response, PFS, OS; LEN + RFA is better |
| LEN + RFA (N=9) | |||||||||
RFA, radiofrequency ablation; BCLC, Barcelona clinic liver cancer; CP, Child-Pugh; TKI, tyrosine kinase inhibitor; SOR, sorafenib; LEN, lenvatinib; OS, overall survival; PFS, progression free survival.